The U.S. Food and Drug Administration (FDA) has approved Infilbray (venglustat) as the first-ever treatment indicated to address the neurological manifestations of Gaucher disease type 3. Developed by Sanofi, the once-daily oral medication was specifically approved for adults and children with type 3 disease who weigh at…
